CAS NO: | 1956370-21-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
生物活性 | RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with anIC50of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome[1]. | ||||||||||||||||
IC50& Target | IC50: 13 nM (RIP1)[1] | ||||||||||||||||
体外研究 (In Vitro) | RIPA-56 shows efficient inhibition of RIP1 kinase activity, with an IC50of 13 nM and no inhibition of RIP3 kinase activity at a 10 μM concentration. RIPA-56 also demonstrates potency in protection of murine L929 cells from TNFα/z-VAD-FMK (TZ)-induced necrosis (EC50=27 nM)[1]. | ||||||||||||||||
体内研究 (In Vivo) | In the SIRS mice disease model, RIPA-56 efficiently reduces tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage. Compared to known RIP1 inhibitors, RIPA-56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies. RIPA-56 has an impressive PK profile in mice with a 3.1 h half-life, 22% oral bioavailability (P.O.), and 100% bioavailability from intraperitoneal injection (I.P.)[1]. | ||||||||||||||||
分子量 | 221.30 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C13H19NO2 | ||||||||||||||||
CAS 号 | 1956370-21-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(451.88 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|